CID/JID/OFID Manuscript Review Program
The Infectious Diseases Society of America offers category 1 CME credit for reviewing manuscripts. Only reviews received on time and judged satisfactory by the Editor(s) responsible for the particular manuscript will be eligible for CME credit. We only provide CME credit to reviewers if they request CME credit at the time they complete their review.
The features that contribute most importantly to the quality of manuscript reviews for the Journal include: adherence to reviewer guidelines, specificity and accuracy, completeness, usefulness of recommendations to both editors and authors, tone, internal consistency, and mindfulness of the needs of our readers and the medical community as a whole.
To prepare a high quality review, the reviewer should consider existing evidence when preparing his or her comments. The reviewer should place the current work in the context of existing evidence in the area, describe the unique contributions of the current work, and comment on any inconsistencies of the current work with previous research in your area.
You will be notified via email if your review of the assigned manuscript was completed on time and if it met our criteria for CME credit.
Accreditation Statement
The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. IDSA designates each manuscript review for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians are eligible for up to 3 CME credits for each manuscript review, up to a total of 15 per year.
Objectives
Through the manuscript peer review process for CID, JID, or OFID, you should be able to:
- integrate new discoveries or observations in infectious disease research that can be applied in your work
- use information resources that improve your ability to treat patients or to conduct research in infectious diseases
- identify articles that provide relevant, new data about infectious diseases that could result in additional knowledge
- apply new information that could result in improved healthcare outcomes
Disclosure Information
In compliance with ACCME’s Standards for Commercial Support of Continuing Medical Education, anyone in a position to influence content is required to disclose any real or apparent conflicts of interest before participating in a CME-accredited educational activity. IDSA, in collaboration with CID, JID and OFID, identifies and resolves all conflicts of interest prior to manuscript reviews.
| Name | Title | Disclosure | Advisory/Consultant | Expert Testimony | Honoraria | Ownership Interests | Stocks/Bonds | Patent/Copyright/License | Other Renumeration | Research Grants/Contracts | Organizational Benefit | Activities with Other Organizations | Family or Other Relations |
| Paul E. Sax | Editor-in-Chief | -- | Gilead, Janssen, Merck, ViiV/GSK | -- | -- | -- | -- | -- | -- | NIH, Gilead, ViiV/GSK | -- | UpToDate | -- |
| Kimberly Hanson | Deputy Editor | -- | Pfizer, Takeda, Quidel, Health TrackRX | -- | -- | -- | -- | -- | -- | NIH | -- | CLSI, ASM, ABIM | -- |
| David A. Pegues | Deputy Editor | -- | DaVita/Total Renal Care, Alexion Pharmaceuticals, ATYU Bioscience, IKEA | -- | -- | -- | -- | -- | -- | AHRQ, PDI Healthcare, NIAID/NIH | -- | -- | -- |
| Maunank Shah | Deputy Editor | -- | -- | -- | -- | -- | -- | Emocha Mobile Health | NIH | -- | National Society of Tuberculosis | -- | |
| Jose R. Arribas | Associate Editor | -- | Gilead, Janssen, Theranos, Sobi, Aelix, Lilly, Astra Zeneca, MSD, Serono, Roche, Sobi, Pfizer, MSD, GSK, ViiV |
-- | -- | -- | -- | -- | MSD, GSK, ViiV | Gilead, ViiV, MSD, Janssen, Roche, Seronoe, HIPRA | -- | -- | -- |
| Sara Hurtado Bares | Associate Editor | -- | -- | Gilead Sciences | -- | -- | -- | -- | ViiV Healthcare, Janssen | -- | -- | -- | |
| Taison Bell | Associate Editor | -- | -- | -- | -- | Owl Peaks Labs | -- | -- | -- | ATS Scholar | -- | ||
| Jose R. Castillo-Mancilla | Associate Editor | -- | -- | -- | -- | -- | -- | -- | Practice Point CME | NIH/NIAID, Gilead Sciences | -- | -- | -- |
| Christina Coyle | Associate Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Jason Gallagher | Associate Editor | -- | Merck, Spero, Astellas, Shionogi | -- | Merck, Spero, Astellas, Shionogi | -- | -- | -- | -- | Merck | -- | -- | -- |
| Rajesh T. Gandhi | Associate Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | NIH | -- | -- | -- |
| Emily L. Heil | Associate Editor | Nothing to disclose | Wolters Kluwer (Lexi-Comp) | -- | -- | -- | -- | -- | -- | Maryland Department of Health | -- | Society of Infectious Diseases Pharmacists | -- |
| Romney Humphries | Associate Editor | -- | Pattern, Qiagen, Torus, Roche, Specific Diagnostics | -- | -- | -- | Qiagen, Specific Diagnostics | -- | -- | Qiagen, bioMerieux, Momentum Diagnostics, Specific Diagnostics | -- | ASM, CLSI, CAP | -- |
| Kerry LaPlante | Associate Editor | -- | Melinta Therapeutics, Ferring Pharmaceuticals Inc. | -- | -- | -- | -- | -- | -- | Merck, Gilead, NIH, Abbvie | -- | MADID, Pharmacotherapy, Infectious Disease and Therapy | -- |
| Ruvandhi Nathavitharana | Associate Editor | Nothing to disclose | World Health Organization | -- | -- | -- | -- | -- | -- | NIH/NIAID, ASTMH | -- | TB Proof | -- |
| Luis Ostrosky-Zeichner | Associate Editor | -- | Cidara, Appillii, Iterum, GigaGen, Takeda, Merck, Octapharma, GSK, F2G | -- | -- | -- | -- | -- | Teva, Stendhal, BSAC, Pfizer, Biotoscana | Scynexis, Pfizer, Pulmocide, Gilead, NIH | -- | ASM, Mycoses Study Group, Immunocompromised Host Society | -- |
| Jean-Jacques Parienti | Associate Editor for Supplements | -- | Gilead, MSD, ViiV | -- | -- | -- | -- | -- | -- | Gilead, MSD | -- | -- | -- |
| Federico Perez | Associate Editor | -- | -- | -- | -- | -- | -- | -- | -- | Merck, Pfizer, Veterans Health Administration | -- | VA Society of Practitioners of Infectious Diseases | -- |
| Adam J. Ratner | Associate Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | Penguin Random House | NIH, CDC Foundation | -- | Pediatric Infectious Diseases Society, American Academy of Pediatrics | -- |
| Chanu Rhee | Associate Editor | -- | Pfizer, Cytovale | -- | -- | -- | -- | -- | UpToDate Inc. | AHRQ, CDC | -- | Society for Critical Care Medicine | -- |
| Nadine Rouphael | Associate Editor | -- | EMMES, ICON | -- | -- | -- | -- | -- | -- | NIH, CDC, Sanofi, Merck, Quidel, Lilly | -- | Vaccines, iScience, ARLG | Siemens |
| Michael J. Rybak | Associate Editor | -- | Merck, Abbvie, Shionogi, T2 Bioscience | -- | -- | -- | -- | -- | -- | NIH, Merck, Tetraphase, T2 | Wayne State University | -- | -- |
| Ilan S. Schwartz | Associate Editor | -- | -- | -- | Mycoses Study Group Education and Research Consortium, AVIR Pharma Inc. | -- | -- | -- | -- | Canadian Institutes of Health Research, Northern Alberta Clinical Trials & Research Centre, F2G | -- | Mycoses Study Group Education & Research Consortium, Mycoses, Journal of the Association of Medical Microbiology and Infectious Diseases of Canada | -- |
| Monica Slavin | Associate Editor | -- | Gilead, Pfizer, F2G, Takeda, Roche | -- | -- | -- | -- | -- | Pfizer, Merck | F2G, NHMRC, Merck | -- | -- | -- |
| Allan Tunkel | State-of-the-Art Reviews Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Tara Vijayan | State-of-the-Art Reviews Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Name | Title | Nothing to Disclose | Advisory/Consultant | Expert Testimony | Honoraria | Ownership Interests | Stocks/Bonds | Patent/Copyright/License | Other Renumeration | Research Grants/Contracts | Organizational Benefit | Family or Other Relations |
| Cynthia Sears | Editor-in-Chief | -- | Ferring | -- | -- | -- | -- | -- | Bristol Myers Squibb, Janssen | -- | -- | |
| Jonathan Li | Deputy Editor | -- | -- | -- | -- | Recovery Therapeutics | -- | -- | Merck & Company | -- | -- | |
| Upinder Singh | Deputy Editor | -- | Regeneron Pharmaceuticals, Gilead Sciences | -- | -- | -- | -- | -- | -- | Regeneron Pharmaceuticals | -- | -- |
| David Andes | Associate Editor | -- | sFunga Therapeutics, Merck & Company, Astellas Pharma, Roche | -- | -- | -- | -- | Forazolines, Cyphomycin, Selvamicin, Turbinmicin, dual-responsive nanoparticle for enhanced antimicrobial efficacy | -- | sFunga Therapeutics, Fedora Pharmaceuticals, Amplyx Pharmaceuticals, Merck & Company | -- | -- |
| Neil Clancy | Associate Editor | -- | Merck & Company, Shionogi & Company, Venatorx Pharmaceuticals, Healthtrax RX | -- | -- | -- | -- | -- | Merck & Company, Cidara | Merck & Company | -- | -- |
| Sara Gianella Weibel | Associate Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Eric Houpt | Associate Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Audrey Odom John | Associate Editor | Pluton Biosciences | -- | -- | -- | -- | Antimalarial therapies, antistaphylococcal therapies (patent pending), malaria diagnostics (patent pending), SARS-CoV-2 diagnostics (patent pending) | -- | -- | -- | -- | |
| Daniel Leung | Associate Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Ighovwerha Ofotokun | Associate Editor | -- | -- | -- | -- | -- | -- | Merck & Company | -- | -- | ||
| Roger Paredes | Associate Editor | GSK, Gilead Sciences, MSD, Theratechnologies, Eli Lilly & Company | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Irini Sereti | Associate Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Jessica Snowden | Associate Editor | Pfizer | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| Jeffrey Tornheim | Associate Editor | Nothing to disclose | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Name | Title | Disclosure | Advisory/Consultant | Honoraria | Other Renumeration | Research Grants/Contracts |
| John W. Baddley | Interim Co-Editor-in-Chief | -- | Pfizer, Lilly, R-Pharm, Horizon Therapeutics, Novo Norodisk | -- | -- | ContraFect Corporation |
| Andrej Spec | Interim Co-Editor-in-Chief | -- | -- | -- | -- | Mayne, Astellas |
| Obinna Nnedu | Associate Deputy Editor for Transfers | Nothing to disclose | -- | -- | -- | -- |
| Samuel Aitken | Associate Editor | -- | GlaxoSmithKline, Shionogi, Entasis Therapeutics | -- | -- | -- |
| Sandra Arnold | Associate Editor | -- | -- | -- | -- | Pfizer, Enanta Pharmaceuticals, Regeneron |
| Joshua Barocas | Associate Editor | -- | Emed | -- | -- | -- |
| Roger J. Bedimo | Associate Editor | -- | Merck & Co., Gilead Sciences, Janssen, ViiV Healthcare | -- | -- | Gilead Sciences, Merck & Co. |
| Donald Forthal | Associate Editor | Nothing to disclose | -- | -- | -- | -- |
| Inge Gyssens | Associate Editor | Nothing to disclose | -- | -- | -- | -- |
| Hannah Imlay | Associate Editor | Nothing to disclose | -- | -- | -- | -- |
| Colleen Kelley | Associate Editor | -- | -- | -- | -- | Moderna, Novavax, Gilead Sciences, Humanigen, ViiV |
| Monica V. Mahoney | Associate Editor | -- | Melinta, Merck, Spero, Medicines Company | Paratek, Tetraphase, Cepheid | Cepheid | Merck |
| Carlos Mejia-Chew | Associate Editor | Nothing to disclose | -- | -- | -- | -- |
| Dylan Pillai | Associate Editor | Nothing to disclose | -- | -- | -- | -- |
| Carlos Seas | Associate Editor | -- | Medicago | Pfizer, Merck Sharp and Dohme | -- | -- |
| Laila Woc-Colburn | Associate Editor | -- | -- | -- | Pri-Med | -- |
| Darcy Wooten | Associate Editor | -- | -- | -- | -- | -- |